Immune health market report
A new report published by Vitafoods Insights provides a comprehensive review of the state of the immune health market. Read more
Latest news
Update 2: Fucoidan and novel coronavirus (COVID-19)
An update on Maritech® fucoidan and COVID-19. Read more
Fucoidan reduces flu severity
Australian researchers have demonstrated that a natural compound derived from seaweed is effective in significantly reducing clinical symptoms and lung damage in a severe Influenza A H1N1 model. Read more
TGA advertising reforms
The Therapeutic Goods Administration (TGA) is Australia's regulatory authority for therapeutic goods. Recent therapeutic goods advertising reforms implemented by the TGA include a stronger compliance framework, an amended Therapeutic Goods Advertising Code, and a single body for compliance and complaints handling. Read more
Nutritional Outlook showcases marine ingredients
Nutritional Outlook magazine has drawn attention to the flourishing marine ingredients market in their April 2020 edition. Read more
Fucoidan nanotechnology advancing cancer research
A recently conducted study involving Marinova's Undaria pinnatifida fucoidan is contributing to cancer research. Read more
Fucoidan as a surface coating for biomaterials
Fucoidan is a promising candidate for the development of new materials in the medical device sector. Read more
Immune health: Ask for the evidence
Marinova encourages manufacturers to look closely at the supporting evidence when considering new ingredients for inclusion in their products. Read more
New findings emerge from world first study
An Australian clinical study has revealed that an extract from the seaweed Undaria pinnatifida influences over 30 different biological pathways and processes. Read more
Fucoidan and novel coronavirus (COVID-19)
Marinova continues to field queries from researchers working to advance potential vaccines and treatments for novel coronavirus (COVID-19). Read more